Keytruda Strikes Out Again in Endometrial Cancer with Phase III Flop | BioSpace

Published: May 09, 2024 By Kate Goodwin

Merck_Sundry Photography/iStock

Pictured: Merck building and sign in Silicon Valley/iStock, Sundry Photography

Merck’s Keytruda swung and missed in endometrial cancer for the second time in six months. Thursday, the pharma giant announced that its bestseller flopped in a Phase III trial in high-risk disease. 

Used as an adjuvant treatment with chemotherapy, with or without radiotherapy for newly diagnosed high-risk patients, the anti-PD-1 treatment did not meet the primary endpoint of disease-free survival compared to placebo at the interim analysis. 

Keytruda already holds two approvals in specified types of endometrial cancer—in combination with Eisai’s Lenvima for advanced, inoperable endometrial carcinoma that has progressed after therapy and as a single agent in similarly diagnosed patients. Merck also has an ongoing development program testing Keytruda in combination with chemotherapy and as a single agent in…
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks


ADVERTISEMENT — Advertise With Biotech Networks